Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,089 total articles
Brookfield Infrastructure (BIP) offers a near-5% yield, inflation-linked contracts and a rapidly expanding data infrastructure business that is benefiting from AI data-center demand. Current technicals show a modest pullback while fundamentals and multiple catalysts argue for a re-rating. This is a swing trade idea sized for income-oriented traders…
Holley (HLLY) is trading at depressed levels that understate its free cash generation and franchise strength in performance and safety products. At a market cap near $293M and an EV/EBITDA of ~7.4x, the stock now offers an asymmetric trade with defined risk. We upgrade to a buy for a mid-term swing (45 trading days) with an entry at $2.45, stop at …
Globe Life checks the boxes for a buy-and-hold trade that captures both dividend income and the upside from potential share repurchases funded by strong free cash flow. The company trades at a reasonable multiple (P/E ~11.6, P/B ~2.24) while delivering high ROE and consistent capital returns. Momentum is strong but short-term indicators are stretch…
Revolve (RVLV) mixes consistent customer growth and margin expansion with improving fundamentals and technical momentum. At a $1.64B market cap and trading near $22.95, the stock offers a medium-risk long opportunity for investors willing to hold into 2026's back half to capture re-rating as margins normalize and AI-driven personalization lifts con…
Entravision (EVC) offers a clean way to buy accelerating programmatic ad revenue (Smadex) inside a broader media company trading at a reasonable EV relative to cash flow. Q2 2025 revenue showed 22% growth in digital while the balance sheet and cash flow metrics leave room for a re-rate. This trade targets a swing move into a re-rating as Smadex mon…
Alphabet remains the best-in-class AI compounder inside Big Tech. Fundamentals (strong free cash flow, high ROE, low leverage) and durable revenue engines - ads, YouTube, Android and accelerating Google Cloud - underpin a constructive multi-month trade. Technicals show a pullback; enter near $345, stop at $330, target $420 on conviction that AI mon…
Transcat operates a niche, mission-critical calibration and instrument-services business that benefits from recurring demand, regulatory attachment, and bolt-on M&A. At roughly $838M market cap, TRNS trades at a premium multiple but offers free cash flow, low leverage, and visible growth—making it a pragmatic long idea with a clear entry, stop and …
Taboola is trading at roughly $4.75 with a market cap near $1.27B, positive free cash flow of $217.7M and a modest P/E ~12. The company's new agentic AI offerings and recent advertiser study suggest material upside to performance advertising on the open web. We upgrade to Buy and lay out an actionable entry, stop and target for a mid-term position.
Smith & Nephew is showing tangible product-level progress in wound care and hospital monitoring while trading near $30. With a $12.8B market cap, a P/E of ~20.5, and new launches that address large, growing end markets, a disciplined long trade using a defined entry at $30.20, a stop at $28.50, and a $36 target offers an asymmetric risk-reward over…
Microsoft's share price has pulled back to $365.45 on heavy volume, testing levels near the 52-week low after headlines and momentum selling. Fundamentals - $2.71T market cap, $72.9B free cash flow, 30% ROE, and a manageable debt load - remain intact. This trade idea targets a rebound to $395 with a stop at $352 on a mid-term (45 trading days) hori…
Sanofi's Dupixent growth trajectory and optionality across new indications are being discounted more aggressively than the fundamentals justify. This trade targets a disciplined long with defined risk controls and a 180-trading-day horizon to let mid-cycle clinical and commercial catalysts play out.
Micron crushed Q3 results and raised guidance, signaling durable AI and data-center demand. The stock is expensive on standard multiples but the combination of multi-year customer contracts, material free cash flow, and low leverage justifies a directional long trade. Entry at $1,200, stop at $1,000, and target at $1,500 over a 45-trading-day swing…
Booking Holdings faces headlines about AI cutting out intermediaries. The more likely outcome is a shifting cost mix and incremental product improvements, not wholesale disintermediation. At $181.27 the stock offers a reasonable entry: attractive free cash flow, positive technical momentum and valuation that already prices in some growth concerns. …
HydroGraph Clean Pwr (HGRAF) is an OTC-listed speculative play on graphene-enabled clean-power technologies. The stock is deeply oversold, trading under key moving averages, and carries very high short interest. For disciplined traders willing to accept high execution and dilution risk, a small starter long with a defined stop and long-term target …
Matson is a focused ocean and logistics operator serving Hawaii and other Pacific markets. With a $5.9B market cap, a sub-14x P/E, nearly $200M in free cash flow, and limited leverage, the stock looks undervalued relative to its cash generation and strategic niche. I rate MATX a Buy with a clear entry, target and stop — for a long-term trade over t…
Copart (CPRT) is an operationally healthy online vehicle auction platform with high returns on capital, robust free cash flow and a valuation that looks reasonable for a mature market leader. Recent earnings hiccups and near-term growth slowdown have pushed the stock below key moving averages; that creates a tradeable entry for investors seeking ex…
Sanmina's $3B purchase of ZT Systems' U.S. data center manufacturing assets and the preferred-partner tie to AMD create a near-term revenue inflection and longer-term margin upside. Valuation is expensive on P/E but reasonable on FCF yield; we upgrade to a buy and propose a trade with a $290 target and $220 stop over a 180 trading-day horizon.
Nanobiotix is a late-clinical stage French biotech developing NanoXray radioenhancers (NBTXR3 / JNJ-1900) and a separate Nanoprimer platform. Recent Phase 2 lung data and a €85m/ ~$100m follow-on that closed in May 2026 give the company runway into 2029. At a $1.72B market cap and current ADS price near $34.04, the stock offers asymmetric upside if…
Armanino Foods (AMNF) is a small-cap specialty foods producer trading at $10.18 with a market cap of $326M. If management follows through on capacity expansion via a new manufacturing facility, the company can convert underutilized fixed costs into higher revenue and cleaner earnings growth. This trade idea targets a move toward $12.50 over a mid-t…
Take-Two (TTWO) is a tradeable long ahead of Grand Theft Auto VI's big launch cycle. The preorder announcement and improving cash flow profile give a clear catalyst; however, high multiples and macro-driven console price pressure justify a defined stop and tempered position sizing.
TIC Solutions' market value sits well below last year's highs, book-value looks reasonable and short positioning is elevated. For traders who want exposure to a beaten-down inspection-and-testing name, a tactical long with a clear stop and a mid-term target offers asymmetric reward-to-risk.
Intel is trading like a very different company than the one that hit a 52-week low in 2025. With a $660+ billion market cap, rapid multiple expansion, and several tangible catalysts - including a U.S. manufacturing push and renewed foundry momentum - I think the market will continue to tolerate a premium valuation. This is a trade, not a long-term …
Airbus just scored a headline-grabbing A220 order that masks a tougher near-term execution picture. The order story is real, but production cadence, margin compression on narrowbodies and military/defense timing create a window for a tactical short. Trade plan included for a mid-term (45 trading days) horizon.
Starbucks is showing signs of a durable turnaround: accelerating comps and margin leverage have driven earnings growth and cash flow stability. Valuation is not cheap, but improving fundamentals and a ~2.4% yield make a mid-term long trade attractive. Entry $103.53, stop $95.00, target $125.00 for a 45-trading-day trade plan.
Viridian has been punished for mixed Phase 3 readouts, but the market may be over-discounting the company's IGF-1R franchise and downstream FcRn assets. With an upcoming FDA decision for veligrotug on 06/30/2026 and a capital base that supports near-term execution, VRDN offers asymmetric upside versus clearly definable downside.
